Abeona Therapeutics Reports Strong Q1 2026 Revenue Growth and Pipeline Update
Abeona Therapeutics posted strong Q1 2026 revenue growth and provided an update on its rare disease gene therapy clinical pipeline during its earnings call. Management discussed ongoing trials, commercial rollouts and affirmed full-year development targets.
1. Q1 Earnings Call Highlights
During its Q1 2026 earnings call, Abeona Therapeutics reported robust revenue gains driven by sales of its gene therapy products for rare diseases. Management detailed progress in ongoing clinical trials, outlined commercial rollout strategies and reiterated its development milestones for the remainder of 2026.
Related News
LIVE
Live Ventures Inc Reports 14.8% Retail Growth, 3.8% Revenue Decline, $2.4M Loss
LIVE•
VIPS
Vipshop Q1 Revenue Up 1.2% to RMB26.6B, GMV Rises 8.6%
VIPS•
AMD
AMD Pledges $10B Taiwan Investment for 2.5D EFB Packaging and Ramps 2nm “Venice” CPUs
AMD•
ZKH
ZKH Group 1Q GMV Rises 12.9% to RMB2.45B; Non-GAAP EBITDA Positive
ZKH•
MKL
Markel Appoints Danny O’Donoghue, 15-Year Fine Art & Specie Underwriter, to Lead London Unit
MKL•
Sources
F